Additional prognostic value of the BCT score in ER+HER2- breast cancer patients receiving a 21-gene assay-guided adjuvant treatments
Our study suggests the utility of the BCT score in stratifying the relapse risk among chemotherapy-untreated patients with a low RS, particularly in young women with an RS of 16-25 who are at risk for long-term recurrence.
Authors
- Eun‐Gyeong Lee (ORCID: https://orcid.org/0000-0002-5345-8846)
- Sang Uk Woo (ORCID: https://orcid.org/0000-0001-6218-4704)
- Sung Gwe Ahn (ORCID: https://orcid.org/0000-0002-8778-9686)
- Joon Jeong (ORCID: https://orcid.org/0000-0003-0397-0005)
- Jai Hyun Chung (ORCID: https://orcid.org/0000-0002-0889-5609)
- Soong June Bae (ORCID: https://orcid.org/0000-0002-0012-9694)
- Seung Ho Baek (ORCID: https://orcid.org/0000-0003-3681-6506)
- Woo Young Kim (ORCID: https://orcid.org/0000-0001-6871-6855)
- Young-Won Lee
- Yeon Jin Kim (ORCID: https://orcid.org/0000-0002-8733-1659)
- Jong Han Yu (ORCID: https://orcid.org/0000-0002-6253-7247)
- Gyungyub Gong
- Seok Jin Nam
- Sae Byul Lee
- Jai Hong Han
- Seok Won Kim
Institutions
- Ulsan College (KR)
- Yonsei University (KR)
- Korea University (KR)
- Korea University Medical Center (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- University of Ulsan (KR)
- National Cancer Center (KR)
- Gangnam Severance Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.3389/fonc.2025.1517073
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Korea Medical Device Development Fund
- Ministry of Trade, Industry and Energy
- Ministry of Food and Drug Safety
- Ministry of Science and ICT, South Korea